10-Q: Cyclo Therapeutics Reports Q3 2024 Results Amidst Proposed Merger and Nasdaq Compliance Challenges

Cyclo Therapeutics reported a net loss for Q3 2024, a decrease in revenue, and is navigating a proposed merger with Rafael Holdings while addressing Nasdaq listing compliance issues.

Summary

• Cyclo Therapeutics reported a net loss of $8.83 million for the third quarter of 2024 and a net loss of $19.16 million for the first nine months of 2024.
• Revenue decreased by 53% in Q3 2024 to $234,000 compared to $495,000 in Q3 2023, and decreased by 27% for the first nine months of 2024 to $559,000 compared to $765,000 in the same period of 2023.
• The company's cash and cash equivalents decreased to $928,010 as of September 30, 2024, from $9,246,592 at the end of 2023.
• Operating activities used $18.22 million in cash for the first nine months of 2024.
• The company has a negative working capital of $15.46 million as of September 30, 2024.
• Cyclo Therapeutics is in the process of a proposed merger with Rafael Holdings, expected to close in late December 2024.
• The company received a delisting notice from Nasdaq due to non-compliance with several listing rules, including minimum share price and equity requirements.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, declining revenue, and a potential delisting from Nasdaq. While there are some positive developments, such as the completion of patient enrollment in the Phase III trial and the proposed merger, the overall sentiment is negative due to the company's financial instability and operational challenges.

Positives

• The company completed enrollment of 104 patients in its Phase III clinical trial for Trappsol Cyclo in May 2024.
• The company received a notice of allowance for a patent application for the treatment of Alzheimer's disease from the USPTO in January 2024.
• The company received a notice of decision from the European Patent Office to grant a patent application regarding methods to treat Alzheimer's Disease in July 2024.
• Rafael Holdings has agreed to fund the company through the merger or termination of the merger agreement.

Negatives

• The company's revenue decreased significantly in both the third quarter and the first nine months of 2024.
• The company's net losses have increased compared to the same periods in the previous year.
• The company's cash reserves have significantly decreased.
• The company has negative working capital.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The company has a material weakness in internal controls related to the accounting of complex equity instruments.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The proposed merger with Rafael Holdings may not be completed.
• The company's reliance on a few major customers for revenue creates a concentration risk.
• The company's research and development expenses are increasing, which may impact profitability.
• The company has a material weakness in internal controls related to the accounting of complex equity instruments.
• The company's ability to utilize net operating loss carryforwards is limited due to an ownership change.

Future Outlook

The company expects to continue to borrow from Rafael Holdings through the consummation of the merger or termination of the merger agreement. If the merger is terminated, the company will need to raise additional capital through the sale of securities or alternative transactions to support ongoing operations and clinical trials. The company's ability to obtain additional capital will be subject to various factors, including business performance and market conditions.

Management Comments

• Management believes expenses will continue to increase as the company continues to conduct clinical trials and seek regulatory approval for Trappsol Cyclo.
• Management is continually evaluating judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities.
• Management has concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024.

Industry Context

The company operates in the biotechnology sector, focusing on rare diseases and neurodegenerative conditions. The development of cyclodextrin-based products is a niche area within the pharmaceutical industry. The company's focus on orphan drug designations and fast-track approvals aligns with industry trends for addressing unmet medical needs. The proposed merger with Rafael Holdings is a strategic move that could provide financial stability and resources for further development.

Comparison to Industry Standards

• Cyclo Therapeutics' revenue decline contrasts with the growth seen in some other biotech companies, particularly those with approved products or late-stage clinical assets.
• The company's high operating losses and negative working capital are concerning compared to industry benchmarks for companies at a similar stage of development.
• The company's reliance on a few major customers for revenue is a risk not typically seen in more diversified pharmaceutical companies.
• The company's research and development spending is significant, but the lack of revenue growth raises concerns about the return on investment.
• The company's Nasdaq delisting notice is a significant negative compared to industry peers that maintain compliance with listing requirements.
• The company's material weakness in internal controls is a concern compared to industry standards for financial reporting.

Related Party Transactions

• The company has entered into multiple convertible note purchase agreements with Rafael Holdings, a major shareholder.

Stakeholder Impact

• Shareholders are at risk of significant losses due to the company's financial instability and potential delisting.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by potential disruptions in the supply of products.
• Creditors may be at risk due to the company's negative working capital and financial instability.

Next Steps

• The company needs to regain compliance with Nasdaq listing rules by April 2, 2025.
• The company needs to complete the proposed merger with Rafael Holdings.
• The company needs to continue its clinical trials for Trappsol Cyclo.
• The company needs to secure additional financing if the merger is terminated.

Key Dates

Keywords

Cyclo Therapeutics, Rafael Holdings, Merger, Nasdaq, Delisting, Trappsol Cyclo, Niemann-Pick Type C, Alzheimer's disease, Clinical trials, Biotechnology, Convertible notes, Financial results, Orphan drug, Cyclodextrins